Benzinga | Aug 13, 2020 07:09AM EDT

HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $12

HC Wainwright & Co. maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and raises the price target from $9 to $12.